# Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes

> **NCT03406585** · PHASE1,PHASE2 · COMPLETED · sponsor: **NextCell Pharma Ab** · enrollment: 24 (actual)

## Conditions studied

- Type1 Diabetes Mellitus

## Interventions

- **DRUG:** ProTrans: Allogeneic transplantation with WJMSCs
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03406585
- **Lead sponsor:** NextCell Pharma Ab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-28
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-09-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03406585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03406585, "Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03406585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*